Creative Medical Technology (NASDAQ:CELZ) Trading Up 5.3% – Here’s Why

Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) rose 5.3% on Monday . The stock traded as high as $2.23 and last traded at $2.17. Approximately 30,890 shares traded hands during mid-day trading, a decline of 39% from the average daily volume of 50,695 shares. The stock had previously closed at $2.06.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Creative Medical Technology in a report on Friday, May 22nd. One analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Creative Medical Technology has a consensus rating of “Reduce”.

Creative Medical Technology Stock Up 5.3%

The business has a fifty day moving average of $2.22 and a 200 day moving average of $2.12. The firm has a market cap of $8.03 million, a P/E ratio of -1.01 and a beta of 1.84.

Creative Medical Technology (NASDAQ:CELZ) last issued its earnings results on Friday, May 8th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.01. On average, sell-side analysts expect that Creative Medical Technology Holdings, Inc. will post -1.57 EPS for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Creative Medical Technology stock. Jane Street Group LLC bought a new position in Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 30,205 shares of the company’s stock, valued at approximately $59,000. Jane Street Group LLC owned 1.17% of Creative Medical Technology as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 1.42% of the company’s stock.

Creative Medical Technology Company Profile

Creative Medical Technology Holdings, Inc (NASDAQ: CELZ) is a clinical?stage biotechnology company focused on the development, manufacture and commercialization of exosome?based therapies derived from human bone marrow mesenchymal stem cells. The company’s proprietary exosome platform is being investigated for applications in regenerative medicine, aesthetic dermatology, wound healing and anti?inflammatory treatments. Creative Medical leverages cGMP manufacturing processes to produce sterile, cell?free exosome formulations designed to support tissue repair and cellular rejuvenation.

The company’s lead product candidates include XoFlo, an exosome enrichment product intended for use in musculoskeletal and soft tissue injuries, and specialized formulations targeting skin rejuvenation and scar reduction.